Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

NCT02392377 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Stage IB Esophageal Adenocarcinoma
Stage IIA Esophageal Adenocarcinoma
Stage IIB Esophageal Adenocarcinoma
Stage IIIA Esophageal Adenocarcinoma
Stage IIIB Esophageal Adenocarcinoma
Stage IIIC Esophageal Adenocarcinoma

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Oxaliplatin
DRUG: Leucovorin Calcium
DRUG: Fluorouracil
RADIATION: Radiation Therapy
PROCEDURE: Therapeutic Conventional Surgery
OTHER: Laboratory Biomarker Analysis

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]